• CAR T-cell Therapy in 2024

  • Apr 12 2024
  • Duración: 29 m
  • Podcast

CAR T-cell Therapy in 2024

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Michael Tees, MD, MPH, Colorado Blood Cancer Institute, Denver, CO Recorded on March 12, 2024 Michael Tees, MD, MPH Director, Lymphoma Program Lymphoma Executive Committee Member, Sarah Cannon Research Institute Associate Member, Colorado Blood Cancer Institute Denver, CO Join Dr. Michael Tees from the Colorado Blood Cancer Institute, as he discusses Chimeric antigen receptor (CAR) T-cell therapy in 2024. Dr. Tees provides an overview of immunotherapy and approved indications, how to discuss treatment options with your patients, what to consider when referring patients for CAR T-cell therapy, how to prepare patients, and educating patients and caregivers about toxicity management. He also provides insight into the limitations of CAR-T therapy, as well as future directions. Tune in to this informative episode today to learn more! This episode is supported by Bristol Myers Squibb, Johnson & Johnson|Legend Biotech, Kite, a Gilead Company, and Novartis Pharmaceuticals Corporation.
    Más Menos
Más Menos

Lo que los oyentes dicen sobre CAR T-cell Therapy in 2024

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles